- Clinically useful anticancer
antibiotics: derived from Streptomyces
- These antibiotics act by:
- DNA intercalation,
blocking synthesis of DNA and RNA
- Anthracyclines:
Doxorubicin (Adriamycin, Rubex, Doxil) and
Daunorubicin (DaunoXome)
- IV administration; hepatic
metabolism; biliary excretion; some
urinary excretion; enterohepatic recirculation.
- Among the most useful
anticancer antibiotics
- Mechanism of
action:
- DNA intercalation
-- blocking synthesis of DNA and
RNA; DNA strands scission -- by
affecting topoisomerase II
- Altering membrane
fluidity and ion transport
- Semiquinone free
radical an oxygen radical
generation (may be responsible
for myocardial damage)
Return to main menu
Carcinomas-Doxorubicin
breast
carcinoma |
ovarian
carcinoma |
thyroid
carcinoma |
endometrial
carcinoma |
testicular
carcinoma |
lung
carcinoma |
Sarcomas-Doxorubicin
Ewing's sarcoma |
osteosarcoma |
rhabdomyosarcomas |
Hematologic
Cancers-Doxorubicin
acute
leukemia |
multiple
myeloma |
Hodgkin's
disease |
non-Hodgkin's
lymphoma |
- Adjuvant therapy in: osteogenic sarcoma
and breast cancer
- Generally used in combination
protocols with:
- cyclophosphamide (Cytoxan)
- cisplatin (Platinol)
- nitrosoureas
- Major Use: Acute Leukemia
- Daunorubicin: limited utility-- limited efficacy in
treating solid tumors.
- Idarubicin: approved for acute myeloid leukemia
- Idarubicin in combination
with cytarabine: more active than
daunorubicin in inducing complete
remission in acute myelogenous leukemia.
- Adverse Effects:
- Bone marrow depression
(short duration)
- Cumulative, dose-related,
possibly irreversible cardiotoxicity.
- Total, severe alopecia
Return
to main menu
-
Adverse Effects:
-
nausea
-
vomiting
-
thrombocytopenia
-
leukopenia
-
hypocalcemia
-
liver toxicity
-
bleeding disorders
-
Mitomycin:
(Mutamycin)
-
Mechanism of action:
-
metabolic activation to
produce a DNA alkylating agent.
-
Solid tumor hypoxic stem
cells may be more sensitive to the action
of mitomycin.
-
Best available drug, in
combination with x-rays, to kill hypoxic
tumor cells.
-
Clinical Use:
-
in combination
chemotherapy {with vincristine and
bleomycin}: squamous sell carcinoma of
the cervix
-
adenocarcinoma of the
stomach, pancreas, and lung {along
with flurouracil and doxorubicin}
-
second-line drug:
metastatic colon cancer
-
topical intravesical
treatment of small bladder papillomas.
-
Adverse Effects:
-
severe
myelosuppression,
especially after repeated doses, suggest
action on hematopoietic stem cells.
-
Vomiting
-
anorexia
-
occasional nephrotoxicity
-
occasional interstitial
pneumonitis
-
Clinical Uses:
-
Testicular cancer
-
Squamous cell carcinoma:
head, neck, cervix, skin, penis, and
rectum
-
combination treatment:
lymphoma
-
intracavity treatment:
malignant effusions in ovarian breast
cancer
-
Adverse Effects:
-
Anaphylactoid reaction
(potentially fatal)
-
Fever
-
anorexia, blistering,
hyperkeratosis (palms)
-
pulmonary fibrosis
(uncommon)
-
No significant
myelosuppression
Return
to main menu
|